

RECEIVED

REFERENCES CITED BY APPLICANTS (Use several sheets if necessary)				ATTY. DOCKET NO. 2254-031-999		APPLICATION NO. 09/644,456			
				APPLICANT HORNİK et al.				FEB 20 2001	
				FILING DATE August 24, 2000				TECH CENTER 1600/2900	
				GROUP Unassigned					
U.S. PATENT DOCUMENTS									
EXAMINER'S INITIALS	PATENT & TRADEMARK OFFICE	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)		
		AA 5,639,455	6/1997	Shimamura et al.	424	133.1			
		AB 5,470,942	11/1995	Alexander et al.	528	328			
		AC 5,420,109	5/1995	Suto et al.	514	8			
		AD 5,210,075	5/1993	Scholz et al.	514	14			
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO		
		AE WO 00/72864 A1	07/2000	PCT					
		AF WO 99/65508	12/1999	PCT					
		AG WO 98/04583	2/1998	PCT					
		AH WO 97/48728	12/1997	PCT					
		AI WO 97/13781	4/1997	PCT					
		AJ WO 97/09344	3/1997	PCT					
		AK WO 95/33765	12/1995	PCT					
		AL WO 95/13086	5/1995	PCT					
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)									
	AM	Hirano, T., 1998, "Interleukin 6 and its Receptor: Ten Years Later", Intern. Rev. Immunol., 16:249.							
	AN	Yoshizaki et al., 1998, "Therapy of Rheumatoid Arthritis by Blocking IL-6 Signal Transduction with a Humanized Anti-IL-6 Receptor Antibody", Springer Semin. Immunopathol., 20: 247.							
	AO	Kozak et al., 1997, "Sickness Behavior in Mice Deficient in Interleukin-6 During Turpentine Abscess and Influenza Pneumonitis", American J. Physiology, 272: 2 R621.							
	AP	Simpson et al., 1997, "Interleukin-6: Structure-function Relationships", Protein Sci., 6: 929.							
	AQ	Xu et al., 1997, "Solution Structure of Recombinant Human Interleukin-6", J. Mol. Biol., 268: 468.							
	AR	Fourcin et al., 1996, "gp130 Transducing Receptor Cross-linking Is Sufficient to Induce Interleukin-6 Type Responses", J. Biol. Chem., 271: 11756.							
	AS	Murakami-Mori et al., 1996, "The Soluble Form of the IL-6 Receptor (sIL-6Ra) Is a Potent Growth Factor for AIDS-associated Kaposi's sarcoma (KS) cells; the Soluble Form of gp130 Is Antagonistic for sIL-6Ra-Induced AIDS-KS Cell Growth", Int. Immunol., 8: 695.							
	AT	Ogata, A., 1996, "Therapeutic Strategies of Inhibition of Interleukin-6 Mediated Multiple Myeloma Cell Growth", Leuk. Res., 20: 303.							
	AU	Sporeno et al., 1996, "Human Interleukin-6 Receptor Super-Antagonists with High Potency and Wide Spectrum on Multiple Myeloma Cells", Blood, 87: 4510.							
	AV	Toniatti et al., 1996, "Engineering Human Interleukin-6 to Obtain Variants with Strongly Enhanced Bioactivity", The EMBO J., 15: 2726.							
	AW	Halimi et al., 1995, "Epitope Peptides from Interleukin-6 Receptor Which Inhibit the Growth of Human Myeloma Cells", Eur. Cytokin. Netw., 6: 135.							
	AX	Klein et al., 1995, "Interleukin-6 in Human Multiple Myeloma", Blood, 85: 863.							

AY	Lu et al., 1995, "Measurement of Whole Body Interleukin-6 (IL-6) Production: Prediction of the Efficacy of Anti-IL-6 Treatments", Blood, 86: 3123.
AZ	Emilie et al., 1994, "Administration of an Anti-Interleukin-6 Monoclonal Antibody to Patients with Acquired Immunodeficiency Syndrome and Lymphoma: Effect on Lymphoma Growth and on B Clinical Symptoms", Blood, 84: 2472.
BA	Grube et al., 1994, "Identification of a Regulatory Domain of the Interleukin-6 Receptor", J. Biol. Chem., 269: 20791.
BB	Kopf et al., 1994, "Impaired Immune and Acute-Phase Responses in Interleukin-6-deficient Mice", Nature, 368: 339-342.
BC	Martin et al., 1994, "The Affinity-selection of a Minibody Polypeptide Inhibitor of Human Interleukin-6", The EMBO J., 13: 5303.
BD	Savino et al., 1994, "Rational Design of a Receptor Super-Antagonist of Human Interleukin-6", The EMBO J., 13: 5863.
BE	Wijdenes et al., 1994, "Interleukin-6 Antibodies in Rheumatoid Arthritis", J. Interferon Res., 14: 297.
BF	May et al., 1993, "Antibodies Chaperone Circulating IL-6", J. Immunol., 151: 3225.
BG	Rokita et al., 1993, "Increased Fibrinogen Synthesis in Mice During the Acute Phase Response: Cooperative Interaction of Interleukin-6, and Interleukin-1 Receptor Antagonist", Cytokine, 5: 454.
BH	Jean et al., 1991, "Diphtheria Toxin Receptor-Binding Domain Substitution with Interleukin-6: Genetic Construction and Interleukin-6 Receptor-Specific Action of Diphtheria Toxin-related Interleukin-6 Fusion Protein", Prot. Eng., 4: 989.
BI	Klein et al., 1991, "Murine Anti-Interleukin-6 Monoclonal Antibody Therapy for a Patient with Plasma Cell Leukemia", Blood, 78: 1198.
BJ	Leser et al., 1991, "Elevation of Serum Interleukin-6 Concentration Precedes Acute-Phase Response and Reflects Severity in Acute Pancreatitis", Gastroenterology, 101: 782: 5.
BK	Milteneburg et al., 1991, "Interleukin-6 Activity in Paired Samples of Synovial Fluid. Correlation of Synovial Fluid Interleukin-6 Levels with Clinical and Laboratory Parameters of Inflammation", British J. Rheumatology, 30: 186.
BL	Novick et al., 1991, "Monoclonal Antibodies to the Soluble Human IL-6 Receptor: Affinity Purification, ELISA, and Inhibition of Ligand Binding", Hybridoma, 10: 137.
BM	Heinrich et al., 1990, "Interleukin-6 and the Acute Phase Response", Biochemistry J., 265: 621.
BN	Stanescu et al., 1987, "Histopathology of Arthritis Induced in Rats by Active Immunization to Mycobacterial Antigens or by Systemic Transfer of T Lymphocyte Lines", Arthritis and Rheumatism, 30: 779.
BO	Hirano et al., 1986, "Complementary DNA for a Novel Human Interleukin (BSF-2) that Induces B Lymphocytes to Produce Immunoglobulin", Nature, 324: 73: 51-70.
EXAMINER	DATE CONSIDERED
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

BEST AVAILABLE COPY